Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProHer: Home vs Hospital Phesgo in HER2+ Breast Cancer
NCT05415215Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Countries
- 17
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05415215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415215.